chitosan has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhakamy, NA; Anwer, MK; Bhattamisra, SK; Choudhury, H; Lim, WM; Md, S; Radhakrishnan, AK; Safian, NH; Shahzad, N; Shak, AT; Xi, LW | 1 |
| Ali, J; Baboota, S; Iqubal, A; Khan, SA; Nabi, B; Nehal, N; Parvez, S; Pathak, A; Rehman, S; Yar, MS | 1 |
2 other study(ies) available for chitosan and oxidopamine
| Article | Year |
|---|---|
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosan; Disease Models, Animal; Dopamine Agonists; Drug Carriers; Female; Haloperidol; Humans; Male; Nanoparticles; Neurons; Oxidopamine; Parkinson Disease, Secondary; Particle Size; Rats; Tetrahydronaphthalenes; Thiophenes; Toxicity Tests, Acute | 2020 |
Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment.
Topics: Animals; Benzoquinones; Chitosan; Disease Models, Animal; Drug Stability; Drug Synergism; Emulsions; Female; Humans; Indoles; Male; Molecular Docking Simulation; Nanoparticles; NF-kappa B; Nigella; Oxidopamine; Parkinson Disease; Plant Oils; Rats; Tumor Necrosis Factor-alpha | 2021 |